Researches and develops Chinese medicines. Manufactures modern Chinese medicines in various forms (soft capsules, granules, injections). Now — the numbers.
This is an established company with proven profits.
No real growth.
If every debt were paid off today, $1.1B would still be left in the vault — a solid cushion for hard times.
The market pays 5.3× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 19% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 30% — still a thick cushion, though costs have been eating into it lately.
There is $1.1B in the vault; even if every debt were paid off, $1.1B would remain.
It pays out $0.08 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales fell about 0% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.